Pegbelfermin clinical trials
Also written BMS-986036.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses Pegbelfermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Studies
Open first, then newest update. How each study uses Pegbelfermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced TrialsCompletedMeridian Bioscience, Inc.NCT03611101Written as BMS-986036
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedPhase 2Bristol-Myers SquibbNCT03486912Written as BMS-986036
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedPhase 2Bristol-Myers SquibbNCT03486899Written as BMS-986036
- A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT04634149Written as BMS-986036
- A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean ParticipantsWithdrawnPhase 1Bristol-Myers SquibbNCT04649710Written as BMS-986036
- Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled SyringeCompletedPhase 1Bristol-Myers SquibbNCT04493567Written as BMS-986036
- A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2Bristol-Myers SquibbNCT02413372Written as BMS-986036
- A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedPhase 2Bristol-Myers SquibbNCT03400163Written as BMS-986036
- A Study of Experimental Medication BMS-986036 Given to Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03445208Written as BMS-986036
- An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney FunctionCompletedPhase 1Bristol-Myers SquibbNCT03674476Written as BMS-986036
- A Study to Evaluate BMS-986036 in Obese Adults With Type-2 DiabetesCompletedPhase 2Bristol-Myers SquibbNCT02097277Written as BMS-986036
- A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese SubjectsCompletedPhase 1Bristol-Myers SquibbNCT03198182Written as BMS-986036
Codes
What other systems call Pegbelfermin · ClinicalTrials.gg INT001058
- MeSH (NLM) C000630067PegbelferminOne source NLM
- UNII (FDA) P5T1E46W5DPEGBELFERMINConfirmed FDA, NLM
- NCI Thesaurus C174833PegbelferminOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630067 | Pegbelfermin | One source NLM |
| UNII (FDA) | P5T1E46W5D | PEGBELFERMIN | Confirmed FDA, NLM |
| NCI Thesaurus | C174833 | Pegbelfermin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.